<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To describe the clinical features, treatment, and outcomes of patients with <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> (aPL)-associated <z:hpo ids='HP_0002072'>chorea</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: The study cohort consisted of consecutive patients with <z:hpo ids='HP_0002072'>chorea</z:hpo> evaluated between 1990 and 2005 with documented aPL at time of their neurologic diagnosis </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: Eighteen patients were identified, 4 with <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE) </plain></SENT>
<SENT sid="3" pm="."><plain>The 14 non-SLE patients experienced 1.6 vascular thromboses/pregnancy losses per person, while patients with SLE experienced 0.5 events/person </plain></SENT>
<SENT sid="4" pm="."><plain>Four non-SLE patients (29%) and no SLE patients met criteria for <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> syndrome (APS) </plain></SENT>
<SENT sid="5" pm="."><plain>None of these 4 tested positive for IgM anticardiolipin antibody (aCL) </plain></SENT>
<SENT sid="6" pm="."><plain>In contrast, 10 (71%) non-APS patients tested positive for IgM aCL </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0002072'>Chorea</z:hpo> was most often bilateral, mild to moderate, and occurred once with a median age at <z:hpo ids='HP_0003674'>onset</z:hpo> of 44 and 33 years in non-SLE and SLE patients, respectively </plain></SENT>
<SENT sid="8" pm="."><plain>Therapy included immunosuppression in 3 (21%) non-SLE patients and in <z:hpo ids='HP_0000001'>all</z:hpo> SLE patients </plain></SENT>
<SENT sid="9" pm="."><plain>Antidopaminergic agents were used in 7 (39%) </plain></SENT>
<SENT sid="10" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients responded to treatment </plain></SENT>
<SENT sid="11" pm="."><plain>Five patients received anticoagulation for <z:mp ids='MP_0005048'>thrombosis</z:mp> and 2 died of <z:mp ids='MP_0001914'>bleeding</z:mp> complications, both non-SLE patients </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSION: aPL-associated <z:hpo ids='HP_0002072'>chorea</z:hpo> occurs most often in women and severity is mild to moderate </plain></SENT>
<SENT sid="13" pm="."><plain>Clinical expression of <z:hpo ids='HP_0002072'>chorea</z:hpo> does not differ between those with and without SLE </plain></SENT>
<SENT sid="14" pm="."><plain>Anticoagulation should be reserved for <z:mp ids='MP_0005048'>thrombosis</z:mp> treatment and not simply for <z:hpo ids='HP_0002072'>chorea</z:hpo> in the presence of aPL, as 2 patients died of <z:mp ids='MP_0001914'>bleeding</z:mp> </plain></SENT>
<SENT sid="15" pm="."><plain>The absence of IgM aCL in patients with APS supports prior evidence that IgG aCL and <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> may be the more clinically relevant antibodies for <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="16" pm="."><plain>However, IgM aCL may be important in patients with <z:hpo ids='HP_0002072'>chorea</z:hpo> </plain></SENT>
</text></document>